Skip to content

DEXMEDETOMIDINE ON ISOFLURANE INDUCED OXIDATIVE STRESS AND DNA DAMAGE IN SURGERY

IMPACT OF DEXMEDETOMIDINE INFUSION ON ISOFLURANE INDUCED OXIDATIVE STRESS AND DNA DAMAGE IN PATIENTS UNDERGOING MAJOR EMERGENCY SURGERY

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100055056
Enrollment
Unknown
Registered
2021-12-31
Start date
2021-04-14
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oxidative stress and DNA Damage

Interventions

A:Isoflurane alone
B:Isoflurane and Dexmedetomidine infusion

Sponsors

University of veterinary and animal sciences, Lahore, Pakistan
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Male patients aged from 18 to 50 years, will be classified by American Society of Anesthesiology (ASA) with physical status of 1-II (including healthy patients with no existing systemic disease other than surgical abnormality) undergoing invasive emergency surgeries lasting for at least four hours will be included in the study.

Exclusion criteria

Exclusion criteria: Diabetics, Overweight individuals, those with recently intake of antioxidant supplements or any medication, those who received radiation recently and elderly patients with decreased intravascular volume as they are prone to hypotension, will be excluded from the study.

Design outcomes

Primary

MeasureTime frame
If Dexmedetomidine is having antioxidant activity, lower level of oxidative stress and DNA damage by the use of Dexmedetomidine infusion with Isoflurane for maintainance of anaethesia will be helpful to overcome these problems during surgery.;

Countries

Pakistan

Contacts

Public ContactDr. Adeel Sattar

University of veterinary and animal sciences

adeel.sattar@uvas.edu.pk03007218004

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026